Anastrozole clinical trials
Also written Arimidex, ZD1033 and ICI-D1033.
ClinicalTrials.gov finds 495 studies for Anastrozole. How that becomes 170 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives Anastrozole. Its counts are asked again every night. How drug pages count
- 495Found by its intervention search · See all 495 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 358 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −14
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor TherapyNCT00066339 · Earlier treatment, not given in this studyReport a problem
- Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast CancerNCT00329940 · Earlier treatment stopped for joint symptoms; the study gives letrozoleReport a problem
- Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast CancerNCT00549822 · Earlier treatment; the study gives letrozole intermittentlyReport a problem
- Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast CancerNCT00688909 · Earlier treatment stopped for joint symptoms; the study gives letrozoleReport a problem
- Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or AnastrozoleNCT00863655 · Earlier treatment; the study gives exemestane with everolimusReport a problem
- Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast CancerNCT01231659 · Earlier treatment; the study gives letrozole with everolimusReport a problem
- A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole TherapyNCT01381874 · Earlier treatment; the study tests abirateroneReport a problem
- 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerNCT01626222 · Earlier treatment; the study gives exemestane with everolimusReport a problem
- A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.NCT01783444 · Earlier treatment; the study gives everolimusReport a problem
- Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneNCT02109913 · Earlier treatment; the study gives everolimus with exemestaneReport a problem
- A Breast Cancer Treatment Decision Aid for Women Aged 70 and OlderNCT02823262 · Named in a decision aid's information, not givenReport a problem
- A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorNCT03312738 · Earlier treatment; the study gives exemestane with everolimusReport a problem
- the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile WomenNCT04619914 · Named only in a description of letrozole; not givenReport a problem
- Skipping Hormone Therapy in Low-Risk Early Breast CancerNCT07661927 · Not given; the study omits endocrine therapyReport a problem
- 481Give Anastrozole to participants
- −63Observe patients on it, or give it outside a trial
- −42Compare another treatment with it
- −206Give it beside what is tested
- 170Test it: the count on this site
Get an email when these change. Save the Anastrozole studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Dec 1995 · ARIMIDEX · NDA 020541 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
170 studies that test it; most in 2005 (12)
| Year | Studies |
|---|---|
| 1996 | 4 |
| 1997 | 1 |
| 1998 | 4 |
| 1999 | 1 |
| 2000 | 2 |
| 2001 | 4 |
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 9 |
| 2005 | 12 |
| 2006 | 10 |
| 2007 | 10 |
| 2008 | 11 |
| 2009 | 4 |
| 2010 | 8 |
| 2011 | 6 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 8 |
| 2015 | 9 |
| 2016 | 6 |
| 2017 | 9 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 8 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 132
AstraZeneca (23) · Fudan University (7) · Mayo Clinic (4) · Massachusetts General Hospital (4) · UNICANCER (3) · Ottawa Hospital Research Institute (3) · Peking Union Medical College Hospital (3) · Alliance for Clinical Trials in Oncology (2)
Often tested with
Tested in the same studies.
Exemestane (39) · Tamoxifen (25) · Letrozole (18) · Fulvestrant (13) · Testosterone (11) · Goserelin (10) · Aromatase inhibitors (8) · Palbociclib (6)
Related medicines
As reviewed, each with the page that says it.
- One of Aromatase inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 15 phase 3 studies under way
Anastrozole is the comparator. A study of two new drugs counts under both.
- 4AZD9833 · AstraZeneca · next primary completion Apr 2027
- 2Elacestrant · Stemline Therapeutics, Inc., European Organisation for Research and Treatment of Cancer - EORTC · next primary completion Aug 2029
- 2HRS-8080 · Shandong Suncadia Medicine Co., Ltd. · next primary completion Aug 2027
- 1Letrozole · Stemline Therapeutics, Inc. · next primary completion Aug 2029
- 1Tamoxifen · Stemline Therapeutics, Inc. · next primary completion Aug 2029
- 1Giredestrant · Hoffmann-La Roche
- 1Palazestrant · Olema Pharmaceuticals, Inc.
- 1Imlunestrant · Eli Lilly and Company · next primary completion Oct 2027
New treatments tested with it · 8 most studied
New when their studies opened, with Anastrozole beside them; studies of each.
Reaching primary completion within a year · 6, 2 in phase 3
Studies that test Anastrozole, phase 3 first.
- Apr 2027Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryPhase 3 · Alliance for Clinical Trials in Oncology
- Apr 2027Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter SyndromePhase 3 · Georgios Papadakis
- Dec 2026Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerPhase 2 · Jonsson Comprehensive Cancer Center
- Jan 2027Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScorePhase 2 · Washington University School of Medicine
- Apr 2027ETHAN - ET for Male BCPhase 2 · Jose Pablo Leone
- Jul 2027Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastPhase 1/2 · Icahn School of Medicine at Mount Sinai
Studies
Open first, then newest update. How each study uses Anastrozole has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 170
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953The standard comparator, and in a testosterone pellet under studyWritten as AnastrazoleHow we knowReport a problem
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingPhase 1Northwestern UniversityNCT07604272Against fulvestrant for inguinal hernia in menWritten as Anastrozole (ARIMIDEX™)How we knowReport a problem
- Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast CancerRecruitingPhase 2Medical College of WisconsinNCT06361940One endocrine option for weeks before surgery; resistance pathways studiedHow we knowReport a problem
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584With fulvestrant and abemaciclibWritten as AnastrozoleHow we knowReport a problem
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07826052One aromatase inhibitor with a CDK4/6 inhibitor, without chemotherapy, in older womenHow we knowReport a problem
- ETHAN - ET for Male BCRecruitingPhase 2Jose Pablo LeoneNCT05501704With or without degarelix and abemaciclib in male breast cancerWritten as AnastrozoleHow we knowReport a problem
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786One endocrine option alone, before or instead of surgery in older womenWritten as AnastrozoleHow we knowReport a problem
- Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low RiskRecruitingPhase 2UNICANCERNCT05297617One aromatase inhibitor for two years instead of fiveHow we knowReport a problem
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerRecruitingPhase 2Peking University People's HospitalNCT06970912One aromatase inhibitor with dalpiciclib before surgery, against chemotherapyHow we knowReport a problem
- Pre-Operative Window of ET to Inform RT Decisions (POWER II)RecruitingPhase 3University of VirginiaNCT06507618One endocrine option for 90 days before surgery, against surgery firstHow we knowReport a problem
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07483307One endocrine option before surgery in lobular breast cancerHow we knowReport a problem
- Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter SyndromeRecruitingPhase 3Georgios PapadakisNCT05586802In men with Klinefelter syndrome, for fertility and metabolic healthWritten as AnastrozoleHow we knowReport a problem
- Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)RecruitingPhase 2Centre Leon BerardNCT03624244One aromatase inhibitor, continued or interrupted, in endometrial stromal sarcomaHow we knowReport a problem
- Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer PatientsRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT07071038One aromatase inhibitor switched to for side effects, against supportive careHow we knowReport a problem
- Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT04553770Added to trastuzumab deruxtecan before surgery in HER2-low cancerWritten as AnastrozoleHow we knowReport a problem
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialNot yet recruitingPhase 3Fudan UniversityNCT07153757One endocrine option for two to three years instead of fiveHow we knowReport a problem
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 3Fudan UniversityNCT07005557One aromatase inhibitor with a CDK4/6 inhibitor, without chemotherapy, in older patientsHow we knowReport a problem
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingPhase 3Region Örebro CountyNCT06223698One aromatase inhibitor in extended adjuvant therapy, against tamoxifen or shorter useWritten as AnastrozoleHow we knowReport a problem
- Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06656624One aromatase inhibitor with ribociclib, against chemotherapy firstHow we knowReport a problem
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)RecruitingPhase 3Peking Union Medical College HospitalNCT05861830One endocrine option with dalpiciclib, against chemotherapyHow we knowReport a problem
See all 170 studies that test Anastrozole →
Tested on its own · 40 — no other medicine in its arm
- Pulmonary Hypertension and Anastrozole TrialCompletedPhase 2University of PennsylvaniaNCT03229499Against placebo in pulmonary arterial hypertensionWritten as AnastrozoleHow we knowReport a problem
- Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast CancerCompletedPhase 3Maastricht University Medical CenterNCT00301457Six against three years after tamoxifenWritten as AnastrozoleHow we knowReport a problem
- STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)Status unknownPhase 3Trans Tasman Radiation Oncology GroupNCT00887380Started before or after radiotherapyWritten as Pre-radiotherapy commencement of anastrozoleHow we knowReport a problem
- Anastrozole Administration in Elderly Hypogonadal MenCompletedPhase 2Massachusetts General HospitalNCT00136695Against placebo in older men with low testosteroneWritten as anastrozoleHow we knowReport a problem
- Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast CancerCompletedPhase 3Queen Mary University of LondonNCT00078832Against placebo to prevent breast cancerWritten as anastrozoleHow we knowReport a problem
- Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal WomenCompletedPhase 2Rita Sanghvi, MehtaNCT00256217Briefly before surgery for DCIS, its effect on Ki-67Written as AnastrozoleHow we knowReport a problem
- Pre-Surgical Intervention for Targeted Therapies for Breast CancerCompletedNot applicableColumbia UniversityNCT01004744Two weeks between biopsy and surgeryWritten as AnastrozoleHow we knowReport a problem
- Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal HysterectomyTerminatedNot applicableUniversity of Sao PauloNCT01280045Before hysterectomy for fibroids, against goserelinHow we knowReport a problem
- Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)CompletedPhase 4Baylor College of MedicineNCT02959853Added to weight loss in obese men with low testosteroneWritten as AnastrazoleHow we knowReport a problem
- Secondary Adjuvant Long Term Study With ArimidexCompletedPhase 3AstraZenecaNCT00295620Two or five more years of extended treatmentWritten as AnastrozoleHow we knowReport a problem
- Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or PlaceboCompletedPhase 2Beth Israel Deaconess Medical CenterNCT00179517Added to testosterone in men with epilepsy and low testosteroneWritten as Anastrozole 1mgHow we knowReport a problem
- Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation TherapyCompletedPhase 3NSABP Foundation IncNCT00053898Against tamoxifen for DCIS after lumpectomyWritten as anastrozoleHow we knowReport a problem
- Bioequivalency Study of Anastrozole 1 mg Under Fed ConditionsCompletedNot applicableRoxane LaboratoriesNCT01155089Bioequivalence of a generic tablet, fedWritten as AnastrozoleHow we knowReport a problem
- Bioequivalency Study of Anastrozole 1 mg Under Fasted ConditionsCompletedNot applicableRoxane LaboratoriesNCT01155102Bioequivalence of a generic tablet, fastedWritten as AnastrozoleHow we knowReport a problem
- Anastrozole in Patients With Pulmonary Arterial HypertensionCompletedPhase 2University of PennsylvaniaNCT01545336Against placebo in pulmonary arterial hypertensionWritten as AnastrozoleHow we knowReport a problem
- Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi SyndromeStatus unknownNot applicableAssistance Publique - Hôpitaux de ParisNCT01520467Against placebo to slow bone maturation in Silver-Russell or Prader-Willi syndromeWritten as AnastrozoleHow we knowReport a problem
- Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis RecurrenceCompletedPhase 4Centre for Endocrinology and Reproductive Medicine, ItalyNCT01769781Added to leuprolide for recurrent endometriosisWritten as anastrazoleHow we knowReport a problem
- Aromatase Inhibitors in the Treatment of Male InfertilityTerminatedPhase 3University of UtahNCT00440180Against placebo in obese men with infertilityWritten as AnastrozoleHow we knowReport a problem
- Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer PatientsCompletedPhase 2Ottawa Hospital Research InstituteNCT01972984Two to six weeks before surgery, a feasibility studyWritten as AnastrozoleHow we knowReport a problem
- Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00588003Briefly before surgery, its effect on gene expressionWritten as anastrozoleHow we knowReport a problem
Showing 20 of 40. See all 40 →
Tested with established drugs · 8 — they are given beside it
- Aromatase Inhibitors and Weight Loss in Severely Obese Men With HypogonadismCompletedPhase 4Baylor College of MedicineNCT03490513Against placebo with weight loss in obese men with low testosteroneWritten as anastrozole (1 mg/day)How we knowReport a problem
- Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.TerminatedPhase 2ARCAGY/ GINECO GROUPNCT02585388One aromatase inhibitor added to metronomic vinorelbineWritten as AnastrozoleHow we knowReport a problem
- Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer PatientsCompletedPhase 2Shanghai Jiao Tong University School of MedicineNCT02440230With ovarian suppression, against exemestane, for bone and joint painWritten as OFS + AnastrozoleHow we knowReport a problem
- Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast CancerCompletedPhase 2SCRI Development Innovations, LLCNCT00405938With bevacizumab, or fulvestrant instead, in metastatic breast cancerWritten as AnastrozoleHow we knowReport a problem
- Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)TerminatedPhase 1Massachusetts General HospitalNCT03118479Given with testosterone to block estrogen, against placeboWritten as Anastrozole PillHow we knowReport a problem
- Impact of Endogenous E2 on SSI and GH ReboundCompletedPhase 1Mayo ClinicNCT02026973Lowering estrogen, alone or with fulvestrant, in a growth hormone studyWritten as AnastrozoleHow we knowReport a problem
- Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal TreatmentCompletedPhase 3AstraZenecaNCT00605267Against tamoxifen with goserelin in premenopausal womenWritten as Anastrazole (Arimidex)How we knowReport a problem
- Arimidex Multicenter Trial in Growth Hormone (GH) Deficient BoysCompletedPhase 2/3Nemours Children's ClinicNCT00133354Added to growth hormone in growth hormone-deficient boysWritten as Arimidex (Anastrozole)How we knowReport a problem
Tested in a combination · 122 — another drug in the study is under test too
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953The standard comparator, and in a testosterone pellet under studyWritten as AnastrazoleHow we knowReport a problem
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingPhase 1Northwestern UniversityNCT07604272Against fulvestrant for inguinal hernia in menWritten as Anastrozole (ARIMIDEX™)How we knowReport a problem
- Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast CancerRecruitingPhase 2Medical College of WisconsinNCT06361940One endocrine option for weeks before surgery; resistance pathways studiedHow we knowReport a problem
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584With fulvestrant and abemaciclibWritten as AnastrozoleHow we knowReport a problem
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07826052One aromatase inhibitor with a CDK4/6 inhibitor, without chemotherapy, in older womenHow we knowReport a problem
- ETHAN - ET for Male BCRecruitingPhase 2Jose Pablo LeoneNCT05501704With or without degarelix and abemaciclib in male breast cancerWritten as AnastrozoleHow we knowReport a problem
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786One endocrine option alone, before or instead of surgery in older womenWritten as AnastrozoleHow we knowReport a problem
- Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low RiskRecruitingPhase 2UNICANCERNCT05297617One aromatase inhibitor for two years instead of fiveHow we knowReport a problem
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerRecruitingPhase 2Peking University People's HospitalNCT06970912One aromatase inhibitor with dalpiciclib before surgery, against chemotherapyHow we knowReport a problem
- Pre-Operative Window of ET to Inform RT Decisions (POWER II)RecruitingPhase 3University of VirginiaNCT06507618One endocrine option for 90 days before surgery, against surgery firstHow we knowReport a problem
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07483307One endocrine option before surgery in lobular breast cancerHow we knowReport a problem
- Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter SyndromeRecruitingPhase 3Georgios PapadakisNCT05586802In men with Klinefelter syndrome, for fertility and metabolic healthWritten as AnastrozoleHow we knowReport a problem
- Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)RecruitingPhase 2Centre Leon BerardNCT03624244One aromatase inhibitor, continued or interrupted, in endometrial stromal sarcomaHow we knowReport a problem
- Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer PatientsRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT07071038One aromatase inhibitor switched to for side effects, against supportive careHow we knowReport a problem
- Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT04553770Added to trastuzumab deruxtecan before surgery in HER2-low cancerWritten as AnastrozoleHow we knowReport a problem
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialNot yet recruitingPhase 3Fudan UniversityNCT07153757One endocrine option for two to three years instead of fiveHow we knowReport a problem
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 3Fudan UniversityNCT07005557One aromatase inhibitor with a CDK4/6 inhibitor, without chemotherapy, in older patientsHow we knowReport a problem
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingPhase 3Region Örebro CountyNCT06223698One aromatase inhibitor in extended adjuvant therapy, against tamoxifen or shorter useWritten as AnastrozoleHow we knowReport a problem
- Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06656624One aromatase inhibitor with ribociclib, against chemotherapy firstHow we knowReport a problem
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)RecruitingPhase 3Peking Union Medical College HospitalNCT05861830One endocrine option with dalpiciclib, against chemotherapyHow we knowReport a problem
Showing 20 of 122. See all 122 →
Beside an established treatment under test · 21 — an approved drug, surgery or radiation is what the study tests
Tested with Anastrozole: Fulvestrant 7 · Gefitinib 3 · Trastuzumab 2 · vistusertib 1 · saracatinib 1 · Nivolumab 1 · lonafarnib 1 · pertuzumab 1
- Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast CancerTerminatedPhase 2Mario Negri Institute for Pharmacological ResearchNCT04113863In every armGiven in both arms before surgery; the study adds ATRAWritten as Anastrozole 1mgHow we knowReport a problem
- A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast CancerCompletedPhase 1/2Joyce Marie Slingerland, MDNCT01216176In every armGiven in both arms before surgery; the study adds saracatinibWritten as AnastrozoleHow we knowReport a problem
- Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)Active, not recruitingPhase 1/2Centre Leon BerardNCT02730923In every armGiven in both arms; the study adds vistusertib in endometrial cancerWritten as AnastrozoleHow we knowReport a problem
- Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs AnastrozoleTerminatedPhase 3Spanish Breast Cancer Research GroupNCT00543127In every armGiven in both arms; the study adds fulvestrantWritten as AnastrozoleHow we knowReport a problem
- A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerCompletedPhase 2Bristol-Myers SquibbNCT04075604In every armGiven in all arms with palbociclib; the study adds nivolumabWritten as AnastrozoleHow we knowReport a problem
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.TerminatedPhase 2University of Maryland, BaltimoreNCT02000596With fulvestrant beside trastuzumab-pertuzumab in one cohortWritten as Hormonal Therapy with Anastrozole and FulvestrantHow we knowReport a problem
- S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast CancerCompletedPhase 3SWOG Cancer Research NetworkNCT00075764In every armGiven in both arms; the study adds fulvestrantWritten as anastrozoleHow we knowReport a problem
- Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast CancerCompletedPhase 2Mothaffar RimawiNCT00570323In every armGiven in both arms before surgery; the study adds fulvestrantWritten as ArimidexHow we knowReport a problem
- Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast CancerTerminatedPhase 2Stanford UniversityNCT00481845In every armGiven in both arms before surgery; the study adds vandetanibWritten as AnastrozoleHow we knowReport a problem
- Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABCWithdrawnPhase 2Fudan UniversityNCT02140437In every armGiven in both arms; the study adds fulvestrantWritten as AnastrozoleHow we knowReport a problem
- Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)CompletedPhase 2Merck Sharp & Dohme LLCNCT00081510In every armGiven in both arms; the study adds lonafarnibWritten as anastrozoleHow we knowReport a problem
- Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast CancerTerminatedPhase 2AstraZenecaNCT01151215In every armGiven in all arms; the study adds AZD8931Written as anastrozoleHow we knowReport a problem
- Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast CancerCompletedPhase 2AstraZenecaNCT00077025Given in both arms; the study adds gefitinibWritten as AnastrozoleHow we knowReport a problem
- Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast CancerCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00066378In every armGiven in both arms; the study adds gefitinibWritten as anastrozoleHow we knowReport a problem
- A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast CancerCompletedPhase 3Hoffmann-La RocheNCT00022672In every armGiven in both arms; the study adds trastuzumabWritten as anastrazole (Arimidex®)How we knowReport a problem
- Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast CancerTerminatedPhase 2Baylor Breast Care CenterNCT00206414In every armGiven in both arms with fulvestrant; the timing of gefitinib is testedHow we knowReport a problem
- Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination TherapyCompletedPhase 3AstraZenecaNCT00256698In every armGiven in both arms; the study adds fulvestrantWritten as AnastrozoleHow we knowReport a problem
- Faslodex Advanced Breast Cancer Local Chinese StudyCompletedPhase 3AstraZenecaNCT00327769In every armGiven in both arms; the study adds fulvestrantWritten as AnastrozoleHow we knowReport a problem
- Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast CancerCompletedPhase 2AstraZenecaNCT00357110In every armGiven in both arms; the study adds fulvestrantWritten as AnastrozoleHow we knowReport a problem
- Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast CancerStatus unknownPhase 3Fudan UniversityNCT00902954In every armGiven in both arms; the study tests switching to exemestaneWritten as anastrozoleHow we knowReport a problem
Showing 20 of 21. See all 21 →
Beside a new treatment under test · 25 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with Anastrozole: abemaciclib 2 · Bireociclib 2 · palbociclib 1 · AZD9833 1 · capivasertib 1 · onapristone 1 · xentuzumab 1 · enzalutamide 1
- Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesEnrolling by invitationNot applicableEnhanced Emirates LimitedNCT07568574An ancillary drug in supervised performance-enhancing regimensWritten as AnastrozoleHow we knowReport a problem
- Ribociclib for HR-positive HER2-negative Metastatic Breast CancerRecruitingPhase 1/2Nagoya City UniversityNCT07164976Partner of ribociclib at two dosesHow we knowReport a problem
- The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in HumansNot yet recruitingNot applicableUniversity of British ColumbiaNCT07212712In every armGiven to men to keep testosterone from turning into estrogenWritten as Anastrozole (Arimidex)How we knowReport a problem
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingPhase 1Hunan Cancer HospitalNCT07163481Partner of sacituzumab govitecan in one moduleWritten as Sacituzumab Govitecan + Anastrozole / ExemestaneHow we knowReport a problem
- PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast CancerActive, not recruitingPhase 2Washington University School of MedicineNCT01723774In every armPartner of palbociclib before surgeryWritten as AnastrozoleHow we knowReport a problem
- Brain Blood Flow Responses to Stress: Sex DifferencesCompletedPhase 4University of Wisconsin, MadisonNCT06253702Given to men to keep testosterone from turning into estradiolWritten as AnastrozoleHow we knowReport a problem
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingPhase 1AstraZenecaNCT03616587Partner of new camizestrant in one partWritten as AZD9833 with anastrozoleHow we knowReport a problem
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingPhase 1AstraZenecaNCT04556773Partner of trastuzumab deruxtecan in one moduleWritten as AnastrozoleHow we knowReport a problem
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingPhase 1Eli Lilly and CompanyNCT02057133Partner of abemaciclib in one armWritten as AnastrozoleHow we knowReport a problem
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT02779751Partner of abemaciclib and pembrolizumab in one breast cohortWritten as AnastrozoleHow we knowReport a problem
- A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to ProgesteroneCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT03909152Partner of new onapristone in some cohortsWritten as Onapristone ER + AnastrozoleHow we knowReport a problem
- A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerActive, not recruitingPhase 3Xuanzhu Biopharmaceutical Co., Ltd.NCT05257395Partner of new bireociclibWritten as XZP-3287+ Letrozole/AnastrozoleHow we knowReport a problem
- This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerCompletedPhase 1Boehringer IngelheimNCT03099174Partner of xentuzumab and abemaciclib in one cohortWritten as AnastrozoleHow we knowReport a problem
- A Phase I/II Study of XZP-3287 in Metastasis Solid TumorsActive, not recruitingPhase 1/2Sihuan Pharmaceutical Holdings Group Ltd.NCT04539496Partner of new bireociclib in one partWritten as XZP-3287;Letrozole;Anastrozole;FulvestrantHow we knowReport a problem
- SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.CompletedPhase 2Tianjin Medical University Cancer Institute and HospitalNCT04836520Partner of new dalpiciclib before surgeryHow we knowReport a problem
- Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleTerminatedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT02476955In every armPartner of new miransertibWritten as ARQ 092 + anastrozoleHow we knowReport a problem
- A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.Status unknownPhase 2Ruijin HospitalNCT04236310In every armPartner of new dalpiciclib with pyrotinib and trastuzumabWritten as AnastrozoleHow we knowReport a problem
- Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerCompletedPhase 1PfizerNCT01597193Partner of enzalutamide in one armWritten as anastrozoleHow we knowReport a problem
- MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerCompletedPhase 1National Cancer Institute (NCI)NCT01344031Partner of new MK-2206, dose-findingWritten as AnastrozoleHow we knowReport a problem
- Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast CancerTerminatedPhase 2National Cancer Institute (NCI)NCT01776008In every armPartner of new MK-2206 before surgeryWritten as AnastrozoleHow we knowReport a problem
Showing 20 of 25. See all 25 →
Beside supportive care · 25 — a supportive treatment or test is studied
- Gonadotropin Therapy in Idiopathic Hypogonadal Non-ObstructiveNot yet recruitingNot applicableIndira IVF Hospital Pvt LtdNCT07540611Allowed beside testosterone-raising gonadotropins in menHow we knowReport a problem
- the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast CancerRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07380646One endocrine partner of ribociclib while leucogen is tested against neutropeniaHow we knowReport a problem
- Study of 18F-FFNP Breast PET/MRIRecruitingPhase 2University of Wisconsin, MadisonNCT06086704Two weeks before surgery while a PET tracer measures responseWritten as AnastrozoleHow we knowReport a problem
- BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderNot yet recruitingPhase 1/2University of Illinois at ChicagoNCT07596212One aromatase inhibitor taken while bupropion is tested for low sexual desireHow we knowReport a problem
- NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast CancerRecruitingPhase 2Washington University School of MedicineNCT05837455Standard first treatment; biomarkers decide who switches to chemotherapyWritten as AnastrozoleHow we knowReport a problem
- A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)Active, not recruitingNot applicableECOG-ACRIN Cancer Research GroupNCT01824836In every armStandard treatment whose joint symptoms are predicted from genesWritten as anastrozoleHow we knowReport a problem
- Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal EstrogenCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT00984399One aromatase inhibitor taken while vaginal estrogen's safety is testedHow we knowReport a problem
- Alcohol and Breast Cancer (ABC) TrialCompletedNot applicableBeth Israel Deaconess Medical CenterNCT05423730One aromatase inhibitor taken while light alcohol's effect on hormones is testedHow we knowReport a problem
- Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast CancerActive, not recruitingPhase 3Kyoto Prefectural University of MedicineNCT03324932One aromatase inhibitor taken while denosumab is tested against bone lossHow we knowReport a problem
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyCompletedPhase 3AmgenNCT00556374One aromatase inhibitor taken while denosumab is tested against fracturesHow we knowReport a problem
- Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast CancerCompletedNot applicableUniversity of Maryland, BaltimoreNCT00641303One aromatase inhibitor taken while acupuncture is tested for joint painHow we knowReport a problem
- Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or LetrozoleCompletedNot applicableOhio State University Comprehensive Cancer CenterNCT01478477One aromatase inhibitor taken while omega-3 is tested for joint symptomsHow we knowReport a problem
- Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase InhibitorsTerminatedNot applicableM.D. Anderson Cancer CenterNCT00738998In every armTaken while joint symptoms are followed by questionnaireHow we knowReport a problem
- Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast CancerTerminatedPhase 3UNICANCERNCT00053911Hormone therapy after surgery for hormone-sensitive relapseWritten as anastrozoleHow we knowReport a problem
- High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D StatusCompletedEarly Phase 1Washington University School of MedicineNCT00263185In every armTaken while high-dose vitamin D is tested for joint symptomsHow we knowReport a problem
- Randomized Anastrozole Exercise TrialStatus unknownPhase 3British Columbia Cancer AgencyNCT00519883In every armTaken while an exercise programme is testedHow we knowReport a problem
- Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast CancerCompletedPhase 2Hackensack Meridian HealthNCT00004900Hormone therapy after the transplant for hormone-sensitive diseaseWritten as anastrozoleHow we knowReport a problem
- Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast CancerCompletedPhase 2Hackensack Meridian HealthNCT00004906Hormone therapy after the transplant for hormone-sensitive diseaseWritten as anastrozoleHow we knowReport a problem
- Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT00005908In every armHormone therapy after chemotherapy, as usual careWritten as AnastrozoleHow we knowReport a problem
- Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm AssessmentCompletedPhase 3Barwon HealthNCT00122356Taken while alendronate is tested against bone lossHow we knowReport a problem
Showing 20 of 25. See all 25 →
One option of several · 135 — a test or a strategy chooses among drugs
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingPhase 1/2RayzeBio, Inc.NCT06590857One endocrine partner of new RYZ101How we knowReport a problem
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialRecruitingPhase 3National Cancer Institute (NCI)NCT07391774In every armOne endocrine partner of ribociclib in both arms; chemotherapy first is comparedWritten as AnastrozoleHow we knowReport a problem
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerNot yet recruitingPhase 2Eli Lilly and CompanyNCT07935317In every armOne endocrine choice beside new tersolisibWritten as AnastrozoleHow we knowReport a problem
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT05894239One optional endocrine therapy with HER2 maintenanceHow we knowReport a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336In every armOne endocrine option in both arms; tersolisib is addedWritten as AnastrozoleHow we knowReport a problem
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751One endocrine option, with a CDK4/6 inhibitor or with saruparibWritten as AnastrozoleHow we knowReport a problem
- Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNot applicableHenan Cancer HospitalNCT07706933One endocrine partner of a CDK4/6 inhibitor after surgeryHow we knowReport a problem
- Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyEnrolling by invitationPhase 3Tolmar Inc.NCT05645536In every armOne endocrine partner of new TOL2506, an extensionWritten as Anastrozole TabletsHow we knowReport a problem
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituRecruitingPhase 1Finn, Olivera, PhDNCT06218303One endocrine option in both arms; a MUC1 vaccine is addedHow we knowReport a problem
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingPhase 2Puma Biotechnology, Inc.NCT06369285One endocrine partner of alisertibHow we knowReport a problem
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303In every armOne endocrine partner of abemaciclib while FFNP-PET predicts responseWritten as AnastrozoleHow we knowReport a problem
- Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07796880One aromatase inhibitor in both arms; new culmerciclib is addedHow we knowReport a problem
- Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast CancerRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07810088One endocrine partner of dalpiciclib and olmesartanHow we knowReport a problem
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersRecruitingPhase 2Ruth O'ReganNCT04886531One aromatase inhibitor with neratinib and trastuzumab before surgeryHow we knowReport a problem
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07782840One aromatase inhibitor in both arms; QL1706 is addedHow we knowReport a problem
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingPhase 2University of California, San DiegoNCT07729046One endocrine option in both arms; neratinib is addedHow we knowReport a problem
- Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07716046In every armOne endocrine option in all arms; fulvestaciclib is addedWritten as AnastrozoleHow we knowReport a problem
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT04469764In every armOne endocrine partner of abemaciclib in hormone receptor-positive tumoursWritten as AnastrozoleHow we knowReport a problem
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingPhase 2Oana DanciuNCT05467891In every armOne endocrine partner of ribociclib after locoregional recurrenceWritten as AnastrozoleHow we knowReport a problem
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingPhase 1/2Tianjin Medical University Cancer Institute and HospitalNCT07708194One endocrine partner of entinostat and pyrotinibHow we knowReport a problem
Showing 20 of 135. See all 135 →
As the comparator · 42 — what is tested is compared with Anastrozole
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781One investigator's choice, against avutometinib and defactinib in ovarian cancerWritten as AnastrozoleHow we knowReport a problem
- A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerNot yet recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07894328One aromatase inhibitor with a CDK4/6 inhibitor, the comparator against HRS-6209How we knowReport a problem
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3AstraZenecaNCT05774951One standard endocrine option, against camizestrantWritten as AnastrozoleHow we knowReport a problem
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT05512364One standard endocrine option, against elacestrantWritten as Anastrozole 1mgHow we knowReport a problem
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07024173One physician's choice, against HRS-8080Written as Anastrozole TabletsHow we knowReport a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingPhase 2MedSIRNCT06486883One endocrine option with a CDK4/6 inhibitor, against trastuzumab deruxtecanHow we knowReport a problem
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05472792One endocrine option, the comparator against partial breast radiationWritten as tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifeneHow we knowReport a problem
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07349069One standard endocrine option, against HRS-8080 after surgeryWritten as Anastrozole TabletsHow we knowReport a problem
- Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)RecruitingPhase 3Japanese Foundation for Cancer ResearchNCT07190443One endocrine option in both arms; abemaciclib is addedWritten as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifenHow we knowReport a problem
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingPhase 2Royal Marsden NHS Foundation TrustNCT04985266One standard endocrine option, against palbociclib with fulvestrantWritten as AnastrozoleHow we knowReport a problem
- Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialRecruitingPhase 2Henan Cancer HospitalNCT06176534One endocrine option, the comparator against chemotherapyHow we knowReport a problem
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceActive, not recruitingPhase 3Stemline Therapeutics, Inc.NCT06492616One standard endocrine option, against elacestrantWritten as AnastrozoleHow we knowReport a problem
- ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast CancerActive, not recruitingPhase 3Azienda Ospedaliero-Universitaria CareggiNCT04134598One endocrine option, the comparator against radiotherapy in women over 70Written as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifenHow we knowReport a problem
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04961996One physician's choice option, against giredestrantHow we knowReport a problem
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingPhase 3AstraZenecaNCT04711252The comparator with palbociclib, against camizestrantWritten as AnastrozoleHow we knowReport a problem
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingPhase 3AstraZenecaNCT04964934The comparator with a CDK4/6 inhibitor, against camizestrantWritten as AnastrozoleHow we knowReport a problem
- Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialSuspendedPhase 3Alliance for Clinical Trials in OncologyNCT06671912One standard endocrine option, against low-dose tamoxifenWritten as AnastrozoleHow we knowReport a problem
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerActive, not recruitingPhase 3Olema Pharmaceuticals, Inc.NCT06016738One standard-of-care option, against palazestrantWritten as AnastrozoleHow we knowReport a problem
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingPhase 3AstraZenecaNCT05952557One standard endocrine option, against camizestrantWritten as AnastrozoleHow we knowReport a problem
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT05514054One standard endocrine option, against imlunestrantWritten as AnastrozoleHow we knowReport a problem
Showing 20 of 42. See all 42 →
Observed · 63 — patients on it are followed, or it is given outside a trial
- Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaRecruitingNovartis PharmaceuticalsNCT06930859One aromatase inhibitor, with or without ribociclib, in Russian practiceWritten as AnastrozoleHow we knowReport a problem
- Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world PracticeRecruitingNovartis PharmaceuticalsNCT06905301One aromatase inhibitor with ribociclib; app use and adherence observedWritten as AnastrozoleHow we knowReport a problem
- A Retrospective Real-world Study of Abemaciclib in HR+ Breast CancerNot yet recruitingThe Affiliated Hospital of Qingdao UniversityNCT06341283With abemaciclib or alone, observed in practiceWritten as Abemaciclib and Letrozole/AnastrozoleHow we knowReport a problem
- Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint TumorNot yet recruitingDR. DIANE CHISESI NFS. MD. PHD.NCT06154590Against tamoxifen, in an observational recordWritten as Method(s)1 AttributionHow we knowReport a problem
- Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World StudyNot yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05801705One aromatase inhibitor with ovarian suppression, observedHow we knowReport a problem
- Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine TherapyRecruitingShengjing HospitalNCT04476485One extended endocrine therapy guided by a predictor, observedHow we knowReport a problem
- Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone TherapyCompletedCity of Hope Medical CenterNCT00681928Cognition in older women taking it, observedWritten as anastrozoleHow we knowReport a problem
- Trifecta Research StudyActive, not recruitingAxial Therapeutic ResearchNCT07717866Part of a hormone supplementation programme, observedHow we knowReport a problem
- Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records DatabasesCompletedBrigham and Women's HospitalNCT07225790With or without abemaciclib, an emulation of MONARCH-3 in recordsHow we knowReport a problem
- First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.Active, not recruitingPfizerNCT04767594One endocrine partner of palbociclib in practice, observedHow we knowReport a problem
- Pilot Observational Study Examining the Effect of Endocrine Therapy on AgingCompletedUniversity of MichiganNCT05700006One aromatase inhibitor; ageing measures observedHow we knowReport a problem
- A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentCompletedNovartis PharmaceuticalsNCT06311383One endocrine partner of ribociclib in German practice, observedHow we knowReport a problem
- A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerActive, not recruitingPfizerNCT06495164One aromatase inhibitor, alone or with a CDK4/6 inhibitor, in US recordsHow we knowReport a problem
- Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.CompletedPfizerNCT06086340One aromatase inhibitor, alone or with palbociclib, in Medicare recordsHow we knowReport a problem
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/LetrozoleCompletedBrigham and Women's HospitalNCT05635357Against exemestane or letrozole, dementia risk in claimsWritten as AnastrozoleHow we knowReport a problem
- Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal DatabaseCompletedSidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01937052One hormone therapy in a longitudinal databaseHow we knowReport a problem
- Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer PatientsCompletedUniversity of Michigan Rogel Cancer CenterNCT01814397One aromatase inhibitor; pain threshold observedWritten as AnastrozoleHow we knowReport a problem
- Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast CancerCompletedMayo ClinicNCT00719966One aromatase inhibitor; blood vessel function observedWritten as anastrozoleHow we knowReport a problem
- Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast CancerCompletedEastern Cooperative Oncology GroupNCT00090974One of two aromatase inhibitors; quality of life observedHow we knowReport a problem
- Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in RussiaStatus unknownBlokhin's Russian Cancer Research CenterNCT05800197Before surgery in Russian practice, observedWritten as Anastrozole 1mgHow we knowReport a problem
Showing 20 of 63. See all 63 →
Codes
What other systems call Anastrozole · ClinicalTrials.gg INT006710
- MeSH (NLM) D000077384AnastrozoleConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2Z07MYW1AZANASTROZOLEConfirmed FDA, NLM, Wikidata
- RxNorm 84857Confirmed FDA, Wikidata
- Wikidata Q419143anastrozoleConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1607AnastrozoleOne source FDA
- DrugBank DB01217One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077384 | Anastrozole | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2Z07MYW1AZ | ANASTROZOLE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 84857 | — | Confirmed FDA, Wikidata |
| Wikidata | Q419143 | anastrozole | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1607 | Anastrozole | One source FDA |
| DrugBank | DB01217 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.